Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
Weill Cornell Medicine Dec 10 2024
Kidney cancer is one of the most frequently diagnosed cancers, striking nearly 82,000 Americans each year, according to the National Cancer Institute, and killing more than 14,000. Roughly 8 in 10 of those diagnoses is for clear cell renal cell carcinoma. One current treatment approach for many cancer types is an immunotherapy called chimeric antigen receptor T-cell therapy, which works by removing immune T cells from the body and genetically engineering them to recognize cancer cells based on the antigens they express. The T cells are then infused back into the patient to trigger an anti-tumor response. This approach has not been successful in patients with kidney cancer.
Related Stories"These dendritic-like reprogrammed tumor cells will help to kill the other tumor cells around them, in part by bringing to the tumor T cells that are already in the patient," said Dr. Gudas, chair of the Department of Pharmacology and the Revlon Pharmaceutical Professor of Pharmacology and Toxicology at Weill Cornell Medicine. "We only need to reprogram a tiny portion of the tumor cell population into dendritic cells to make this treatment strategy successful.
Kidney Kidney Cancer Antigen Carcinoma Cell Immune System Immunotherapy Medicine Pharmacology Renal Cell Carcinoma Tumor
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
EZH2 enzyme drives aggressive tumor growth in treatment-resistant prostate cancerAn enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.
Read more »
Fungus found in the mouse stomach may hold a key to fungal evolution in the gutA fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators.
Read more »
Tirzepatide cuts diabetes risk by 90% in obese patients, study showsTirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine...
Read more »
Study reveals how brainstem neurons control eye movementsWorking with week-old zebrafish larva, researchers at Weill Cornell Medicine and colleagues decoded how the connections formed by a network of neurons in the brainstem guide the fishes' gaze.
Read more »
Study reveals the secret to cellular youth may lie in nucleolus sizeThe secret to cellular youth may depend on keeping the nucleolus—a condensed structure inside the nucleus of a cell—small, according to Weill Cornell Medicine investigators.
Read more »
Psychological stress and pain contribute to cardiovascular disease in asylum seekersMany individuals seeking asylum in the United States show increased stress and pain symptoms that are associated with indications of cardiovascular disease according to Weill Cornell Medicine researchers.
Read more »